 鲜花( 85)  鸡蛋( 2)
|

楼主 |
发表于 2015-2-28 21:48
|
显示全部楼层
Stock soars after Cold-fX wins crucial approval
; H& [" s$ ^7 o3 H' ^- {+ q
! n9 g! n% ]$ ^6 h! kEDMONTON - CV Technologies Inc. shares rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.
. P% B8 t: l. u8 I+ [
4 w- [, x+ a! I8 l9 pBY THE EDMONTON JOURNAL FEBRUARY 16, 2007
+ W) `8 v- D# P: `7 U 6 u. I$ k" Q' X
* t3 W& P% l8 d9 D6 V- F* K; ]
EDMONTON - CV Technologies Inc. SHARES rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.
& P" _$ s0 {! J1 h) L
3 I- H! v; f8 x, y' b" rThe agency said CV Technologies can continue to market Cold-fX as helping "to reduce the frequency, severity and duration of cold and flu symptoms by boosting the IMMUNE SYSTEM."
: T' {) W9 X4 b& x2 @ {& n
7 G5 Y4 N( G7 Q( F- G+ oThe APPROVAL follows a review of seven clinical trials and more than 10 years of research about the product.$ j0 W" w! x/ Z0 d o9 t) w8 p+ f- ^
2 e) x4 ]" G5 B7 z3 h! T4 M
It should create even more confidence among consumers and medical professionals that the product works, CEO Jacqueline Shan said Thursday.
7 G6 p$ ^! V1 k& h* P
$ P# s7 A7 R- Y( `It certainly instilled confidence in the market, as shares closed at $2.90 on THE TORONTO STOCK EXCHANGE, up $1.08 on a volume of 4.6 million.' ^/ ^0 {! z5 ^7 T1 j, o5 ]
! Z! m0 i* ^/ ]
"As a scientist, it's one of the highlights of my CAREER," Shan said.
% \& D* C7 h& `4 \9 b. n9 n0 `
! O& |& x1 l5 @ ?# @9 |' a"This approval is a breakthrough in realizing our vision of being a global leader in developing products for disease prevention."
& t5 K/ @" T# Y9 W4 G" M& u) b
1 ?" G) W ~; ]9 \3 @: `It's Cold-fX's strongest medical recognition to date, said Shan. It means the company can advertise the HEALTH BENEFITS more effectively to consumers and health professionals, she said., a- r+ [( r3 z" i0 o1 Y9 z0 [4 e8 A
+ r) e2 Z; Q jGinseng-based Cold-fX is already the top-selling cold and flu treatment in Canada, but Shan said there is plenty of room for more growth.% r' u$ S' D) ]' E; X3 g' _! z* V
. B0 u, ]# q. F' }8 ^
The approval will also help raise the product's PROFILE in the lucrative U.S. market, which Cold-fX entered in October. The move came with a new marketing push, using former Oilers superstar Mark Messier as its spokesman.: D0 i) M7 n3 u# C
) z0 K1 n( }+ v9 X# B0 I0 @; p: A# Z" m
: h# ?0 A- A$ M7 ?& [! J5 Ghttp://www.canada.com/story.html ... 9-be80-f40f1426f662 |
|